The prognostic effect of increased resting energy expenditure prior to treatment for lung cancer

Objective: Increased resting energy expenditure (REE) is thought to confer a poor prognosis in patients with non-small cell lung cancer (NSCLC). However, no study has validated this hypothesis to date. This study’s objective was to examine the prognostic significance of REE in NSCLC. Methods: Sevent...

Full description

Saved in:
Bibliographic Details
Published in:Lung cancer (Amsterdam, Netherlands) Netherlands), 1999-02, Vol.23 (2), p.153-158
Main Authors: Jatoi, Aminah, Daly, Benedict D.T., Hughes, Virginia, Dallal, Gerard E., Roubenoff, Ronenn
Format: Article
Language:English
Subjects:
Aged
Basal Metabolism
Biological and medical sciences
Body Mass Index
Calorimetry, Indirect
Carcinoma, Non-Small-Cell Lung - metabolism
Carcinoma, Non-Small-Cell Lung - mortality
Carcinoma, Non-Small-Cell Lung - pathology
Carcinoma, Non-Small-Cell Lung - therapy
Energy expenditure
Female
Follow-Up Studies
Humans
Indirect calorimetry
Lung cancer
Lung Neoplasms - metabolism
Lung Neoplasms - mortality
Lung Neoplasms - pathology
Lung Neoplasms - therapy
Male
Medical sciences
Metabolism
Neoplasm Staging
Pneumology
Predictive Value of Tests
Prognosis
Regression Analysis
Survival Analysis
Tumors of the respiratory system and mediastinum
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective: Increased resting energy expenditure (REE) is thought to confer a poor prognosis in patients with non-small cell lung cancer (NSCLC). However, no study has validated this hypothesis to date. This study’s objective was to examine the prognostic significance of REE in NSCLC. Methods: Seventeen patients with NSCLC (stages IA–IIIB) underwent measurement of REE with indirect calorimetry before the initiation of cancer treatment. Similar measurements were performed in 17 control subjects, each of whom was matched to a cancer patient by age (±5 years), sex and body mass index (±3 kg/m 2). Patients were classified as hypermetabolic or hypometabolic based on a direct comparison of measured REE between cancer patients and their matched controls. After cancer treatment, these 17 patients were followed for evidence of metastatic disease for up to 32 months. Results: Six patients developed metastatic disease. The eight hypometabolic cancer patients had a significantly shorter mean disease-free survival compared to the nine hypermetabolic cancer patients: 19 months (95% confidence interval (CI) 12, 26) versus 29 months (95% CI 24, 34), respectively ( P
ISSN:0169-5002
1872-8332
DOI:10.1016/S0169-5002(99)00008-2